INVIVO EFFECTS OF MURINE HYBRIDOMA MONOCLONAL-ANTIBODY IN A PATIENT WITH T-CELL LEUKEMIA

  • 1 January 1981
    • journal article
    • research article
    • Vol. 58  (1) , 78-86
Abstract
A murine monoclonal antibody directed against a normal T-cell differentiation antigen was given to a patient with adult T-cell leukemia. Immunofluorescence staining showed increased amounts of this antigen on the patient''s leukemia cells. Using a competition radioimmunoassay, free antigen was not detectable in the serum prior to therapy. Two courses of in vivo therapy were given using a 1-mg dose. Each produced a prompt and dramatic fall in WBC [white blood cell count] with return to pretreatment levels over the ensuing 24 h, a pattern similar to that seen with leukopheresis. After the 1st dose of antibody, circulating free antigen became detectable in the serum and a transient decline in creatinine clearance was noted. A 5-mg dose of antibody given at that time was ineffective, presumably because it was blocked by free antigen. Antigenic modulation by leukemia cells was found transiently following each course of antibody. A weak and clinically insignificant host antimouse antibody response was found 5 days after the 1st treatment. The patient tolerated antibody therapy without difficulty.